Drug shortage: Lisdexamfetamine Dimesylate Capsule (LISDEXAMFETAMINE DIMESYLATE, VYVANSE)
FDA lists 90 presentations as Current. Availability: Limited Availability (36), Available (54). Reason: Shortage of an active ingredient; Other. Companies: Hikma Pharmaceuticals USA, Inc., Amneal Pharmaceuticals, Alvogen, SpecGx LLC, Apotex Corp.….
- Published by source
- 2023-07-14
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Hikma Pharmaceuticals USA, Inc.
- Products
- Lisdexamfetamine Dimesylate Capsule LISDEXAMFETAMINE DIMESYLATE VYVANSE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Limited Availability
Remedy / actions:
- Available on allocation
- Estimated recovery: TBD
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2023-07-14
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #877 | new | 2026-10-22 | 632aca42e334…104cc6 | 42e90e067776…221d35 |
Chain head: #1094 edf3be25ec2e…478842